Molecular medicine

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Cell culture #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #Precision medicine #Regulatory #RNA #Screening #Sequencing #Therapeutics #Toxicology

Evaluating future drug candidates and their manufacture together

Evaluating future drug candidates and their manufacture together By Professor Peter Dunnill Classically, evaluating a candidate drug has preceded evaluation of the process for making it. The late rush to process development worked reasonably well with simple chemical pharmaceuticals. With complex biopharmaceuticals, a new approach is needed. One now being… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Chemical engineering #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Oncology #Organic chemistry #PCR #Protein chemistry / Proteomics #Screening #Sequencing #System biology

Chemogenomics – A gene family approach to parallel drug discovery

Chemogenomics - A gene family approach to parallel drug discovery By Dr Paul R. Caron, Dr Michael D. Mullican, Dr Robert D. Mashal, Dr Keith P. Wilson, Dr Michael S. Su and Dr Mark A. Murcko Currently available drugs only target around 500 different proteins (4). Recent reports from efforts… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Pathology #Pharmacogenomics #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Target validation

The Impact of Genomics on Regulation

The Impact of Genomics on Regulation By Dr Steve Arlington, Dr Tim Peakman, Adriana Salvatore and Jonathan Peachey Advances in science and technology are enabling us to understand physiology and pathology at a totally new level; to define, subtype and track diseases much more accurately; and to treat patients far… Read More

#Archive

#Analysis #Animal models #Automation / robotics #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #Lead discovery #Molecular medicine #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #System biology #Target validation #Therapeutics #Toxicology

New Developments in Analgesia

New Developments in Analgesia By Dr Susan Boyce, Dr Zahid Ali and Dr Raymond G. Hill Novel therapies for pain and headache are major medical needs and constitute a continued opportunity. Novel treatments are likely to arise from a better understanding of both the pathophysiology of clinical pain conditions and… Read More

#Archive

#Animal models #Assay development optimisation & technology #Biochemistry #Biomarkers #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Imaging #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Pharmacogenomics #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology #Systems biology #Toxicology

Surrogate Endpoints In Cancer Trials

Surrogate Endpoints In Cancer Trials By Professor Karol Sikora Over the next 20 years systematic programmes of cancer risk assessment will be established and cancer-preventive drugs will be developed. The ability to prevent cancer will dramatically increase the number of people who will need to regularly attend clinics. This article… Read More

#Archive

#Analysis #Business #Cell therapy #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Molecular medicine #Pharmacogenomics #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Target validation #Translational #Translational chemistry

Protein Arrays – New technology for the proteomics era

Protein Arrays - New technology for the proteomics era By Dr Jeffrey P. Kiplinger The study of the human proteome will drive drug discovery in coming years; although how, when, and in what direction are a little uncertain at present. To build understanding of the role of the human protein… Read More

#Archive

#Analysis #Biomarkers #Business #Clinical specialities #Drug development #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Molecular medicine #Oncology #Pathology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology

Pharmacogenetics – A review of concepts and contents

By Professor Klaus Lindpaintner Pharmacogenetics represents a logical and consequent step in the history of medicine, but what are the immediate benefits and where do the hurdles lie in its implementation? It is common knowledge that today’s pharmacopea – in as much as it represents enormous progress if compared with… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Animal models #Automation / robotics #Business #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Pharmacogenomics #Regulatory #RNA #Screening #Target validation #Toxicology

Biologically Relevant Chemistry

Biologically Relevant Chemistry By Dr Stephen A. Hill A large proportion of R&D expenditure relates to the investigation of compounds which ultimately fail to reach the market as useful medicines. We discuss why early drug discovery - using high throughput, automated in vitro and in silico methods, must become the… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Medicinal chemistry #Microbiology #Molecular medicine #Oncology #Organic chemistry #Pathology #PCR #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

Increasing the chances of lead discovery

Increasing the chances of lead discovery By Sandra Fox, MBA, Dr Helen Wang, Dr Lynne Sopchak and Dr Richard Khoury For HTS laboratories worldwide, the mission is to supply therapeutic groups in the shortest time possible with high quality hits and leads that will become drug candidates. Mounting pressure to… Read More

#Archive

#AI / data analytics / healthtech / informatics #Animal models #Biochemistry #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Immunology #Molecular medicine #Oncology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics

The Genie in the Test Tube – From Gene to Gene Therapy: Part 2

The Genie in the Test Tube - From Gene to Gene Therapy: Part 2 By Dr Jan Steiner In the previous edition, we discussed gene therapy in terms of potential vectors and their applications. Now, we discuss the potential clinical uses of these constructs. To date, the main applications of… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Business #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #Immunology #Lead discovery #Molecular medicine #Pharmacogenomics #Protein chemistry / Proteomics #RNA

The promise of pharmacogenetics and pharmacogenomics

The promise of pharmacogenetics and pharmacogenomics By Dr Tim Peakman and Dr Steve Arlington Within the next 10 years the benefits of pharmacogenetics and pharmacogenomics will inevitably outweigh the disadvantages. But what are the commercial and legal implications for the pharmaceutical industry especially for companies who have lead candidates ready… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development & optimisation #Chemistry #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Microbiology #Molecular medicine #Screening #Sequencing #Stem cells #System biology #Systems biology #Translational #Translational chemistry

The Industrialisation of Bioinformatics

The Industrialisation of Bioinformatics By Dr Alex Titomirov With the completion of the ‘draft’ sequence of the human genome predicting an estimate of 40,000-120,000 genes that describe us, the real work begins. The problem now is not lack of data but lack of tools to thoroughly analyse what we already… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #PCR #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation

Exploiting the fruits of the human genome – A strategic perspective

By Dr David C. U’Prichard It is almost axiomatic that the pharmaceutical R&D industry has not achieved in the last decade an increase in productivity (measured as high value NCEs) commensurate with the explosion of new biological information, chemistry techniques and information storage/retrieval/examination systems, let alone the real increase in… Read More

#Archive

#Academic #Analysis #Analytical chemistry #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomics #Genomics #High throughput screening #Lead discovery #Molecular medicine #Oncology #Pharmacogenomics #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #System biology #Therapeutics #Toxicology

Pharmacogenomics – A new paradigm for drug development

By Michael P. Murphy, MSc Pharmacogenomics offers the opportunity to adopt a new paradigm in drug development. The pharmaceutical industry is faced with a number of challenges including relatively low productivity and success in bringing new drugs to market. Investors demand that pharmaceutical companies deliver several new drugs to the… Read More

#Archive

Genome editing
#AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Cellular & Molecular biology #Clinical trials #Drug development #Drug discovery #Genetics / genomes #Genetics / genomics #Genomics #Lead discovery #Molecular medicine #Preclinical #RNA #Sequencing #System biology #Systems biology #Toxicology

The role of toxicogenomics in drug discovery

The role of toxicogenomics in drug discovery By Dr Robin E. Neft and Dr Spencer Farr The information that toxicogenomics can bring in terms of toxic mechanisms, safety and efficacy must ultimately have a major impact on the drug discovery process. Large scale genome sequencing has lead to elucidation of… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cellular assays #Chemical engineering #Clinical trials #Drug development #Drug discovery #Drug targets #Genomics #Lead discovery #Molecular medicine #Nanomedicine / nanotechnology #Pharmacogenomics #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Toxicology

Harnessing the CRO Intellect

Harnessing the CRO Intellect By Ian Lennox and Dr Nigel Brown There is no question that pharmaceutical companies are qualified to perform their own discovery and preclinical research. However, to fully exploit the new technologies in the early research phases, to maximise drug leads, and to minimise costs, would the… Read More

#Archive